Marcia Brose, MD, leads trial that shows personalized therapies for thyroid cancer patients are effective


June 1, 2009

Penn Medicine News Release

(ORLANDO) – In what researchers are calling a breakthrough, patients with thyroid cancer that is resistant to radioactive iodine therapy were found to respond well to sorafenib, a researcher reported today at the annual meeting of the American Society of Clinical Oncology (ASCO). The phase II clinical trial data highlight an intensive effort at the University of Pennsylvania School of Medicine Abramson Cancer Center to develop effective, personalized therapies for these patients, who have previously had few options for treatment... Read More